ATN 110 Antiretroviral Medications in Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-exposure Prophylaxis Use Among Young Men Who Have Sex With Men (YMSM) in the United States

Data from Antiretroviral Medications Form R1 [CRF 5]
Study Description
A pre-exposure prophylaxis (PrEP) demonstration project and Phase II safety study to obtain additional data on the safety of emtricitabine/tenofovir (FTC/TDF (Truvada®)) and evaluate patterns of use, rates of adherence, and patterns of sexual risk behavior among YMSM (inclusive of transgender women) who were provided with open label FTC/TDF and information on the safety and efficacy of PrEP from prior studies. This project also explored the feasibility and acceptability of implementing two different efficacious risk reduction interventions prior to provision of PrEP - Many Men, Many Voices (3MV) and Personalized Cognitive Counseling (PCC).
HIV-1 uninfected young men who have sex with men, ages 18-22 years

抗逆转录病毒药物R1表单数据 [病例报告表5（CRF 5）]
研究概况
本研究为一项暴露前预防（PrEP）示范项目与II期安全性研究，旨在补充获取恩曲他滨/替诺福韦（FTC/TDF，商品名Truvada®）的安全性数据，并评估接受开放标签FTC/TDF给药及既往PrEP安全性与有效性相关信息的年轻男男性行为者（Young Men Who Have Sex with Men, YMSM，含跨性别女性）群体中的药物使用模式、依从率及性风险行为模式。本项目同时探索了在提供PrEP前实施两种高效风险降低干预措施的可行性与可接受性——即“众男众声（3MV）”项目与个性化认知咨询（PCC）。
研究对象为18~22岁、未感染HIV-1的年轻男男性行为者（含跨性别女性）。